Bristol-Myers Squibb and AbbVie receive FDA approval of Empliciti™ (elotuzumab)
Bristol-Myers Squibb announced the FDA has approved Empliciti (elotuzumab) for treatment of multiple myeloma as combination therapy with Revlimid® (lenalidomide) and dexamethasone in patients who have received one to three prior therapies. November 30, 2015